Podcasts about Roche Diagnostics

Our guest on this 46th episode of the 2025 season—celebrating Asian American and Pacific Islander Heritage Month—is Kaye Vitug, senior vice president and chief financial officer at Roche Diagnostics. Vitug shares her powerful personal and professional journey from growing up in the Philippines to becoming a top financial executive in the global pharmaceutical and diagnostics industry. She reflects on the values of education, service, faith and community that shaped her leadership style, and discusses the challenges of immigrating to the United States and navigating a corporate career as a Filipino American woman. Vitug also speaks about the importance of cultural agility, drawing from her global experiences in California, the United Kingdom, South Korea, Switzerland and now Indiana. She offers valuable insight into the responsibilities of a CFO, the importance of authenticity in leadership, and the role that mentorship, coaching and sponsorship play in developing emerging leaders—particularly those from diverse backgrounds. She emphasizes resilience, humility and strategic thinking as essential qualities for success, and shares how her career has been shaped by leaders who took a chance on her potential. This episode is a thoughtful reflection on inclusive leadership, global experience and the importance of creating environments where all professionals can thrive.

Amid pressure from President Donald Trump's tariffs, Roche Diagnostics announces a $500 million investment into its Indianapolis facility that makes glucose monitoring systems.

In this episode of Inside INdiana Business with Gerry Dick, global innovation arrives in a bigger way in Indiana. Silicon Valley-based Plug and Play is expanding to the new IU Launch Accelerator at 16 Tech, aiming to recruit and grow life sciences startups in Indianapolis and connect them with Warsaw's growing medtech hub. CEO Saeed Amidi says Indiana's combination of university talent and global companies like Eli Lilly makes it a powerful new frontier for innovation. Plus: How the new IU Health incubator at 16 Tech could transform Indianapolis into a national player in biosciences. Roche Diagnostics and Eli Lilly announce major U.S. manufacturing expansions, with the potential for Indiana to land more investment. Community Health Network opens the first phase of its Westfield campus, featuring AI-assisted patient care. A new Ronald McDonald Care Mobile rolls out in Evansville to combat Indiana's high infant and maternal mortality rates. Also in this episode: Ports of Indiana-Mount Vernon launches a new railroad to drive economic development. Terre Haute's Hulman Field Air Base plans a new $13 million small arms training range. Fort Wayne breaks ground on an 8,400-seat soccer stadium ahead of joining USL League One. A Noble County fire department auctions off a pumper truck to fund new equipment. Gaylor Electric becomes the first company to twice win National Contractor of the Year honors. IU Indianapolis expands STEM research space with a new lab building at 16 Tech. Ball State completes a $60 million renovation of Cooper Science Building. Indiana Tech launches a new advanced manufacturing innovation center at Electric Works in Fort Wayne. And: Hud Mellencamp and Hard Truth Distilling launch a new whiskey celebrating Indiana farmers and the Mellencamp legacy. The Pacers surge ahead in the NBA Playoffs as Caitlin Clark and the Indiana Fever prepare for a historic season. Inside INdiana Business previews next week's kickoff of Business at the Brickyard coverage at the Indianapolis Motor Speedway.

Rick Sherak, CEO of Exokinetics, shares his incredible journey from serving as an Air Force officer to leading a company that develops transformative mobility devices. He discusses the importance of leadership, sales psychology, and creating compassionate company culture. Rick's passion shines through as he recounts heartwarming stories of how Exokinetics' Zeen device has profoundly improved the lives of people with mobility challenges, including children with cerebral palsy.   Guest links: https://gozeen.com/ | https://vimeo.com/1011399920 | https://vimeo.com/856975581/9994ad1cb8?share=copy Charity supported: Project ELEVATE Mobility Interested in being a guest on the show or have feedback to share? Email us at theleadingdifference@velentium.com.  PRODUCTION CREDITS Host: Lindsey Dinneen Editing: Marketing Wise Producer: Velentium   EPISODE TRANSCRIPT Episode 053 - Rick Sherak [00:00:00] Lindsey Dinneen: Hi, I'm Lindsey and I'm talking with MedTech industry leaders on how they change lives for a better world. [00:00:09] Diane Bouis: The inventions and technologies are fascinating and so are the people who work with them. [00:00:15] Frank Jaskulke: There was a period of time where I realized, fundamentally, my job was to go hang out with really smart people that are saving lives and then do work that would help them save more lives. [00:00:28] Diane Bouis: I got into the business to save lives and it is incredibly motivating to work with people who are in that same business, saving or improving lives. [00:00:38] Duane Mancini: What better industry than where I get to wake up every day and just save people's lives. [00:00:42] Lindsey Dinneen: These are extraordinary people doing extraordinary work, and this is The Leading Difference. Hello and welcome back to another episode of The Leading Difference podcast. I'm your host, Lindsey, and I am so excited to introduce you to my guest today, Rick Sherak. After serving as an Air Force officer, Rick spent over 25 years in the medical diagnostic industry as a commercial and product development executive. Leveraging his broad leadership and medical domain experience, he became CEO of Exokinetics in March 2024 to lead the company into its next expansion phase of market awareness and revenue growth.  Alrighty. Well, welcome, Rick, to the show. Thank you so much for joining me today. I'm so excited to speak with you. [00:01:30] Rick Sherak: Well, it's nice to meet you, Lindsey, and I'm glad to speak with you today as well. Should be fun. [00:01:36] Lindsey Dinneen: Yeah. Excellent. Well, I would love if you would start by sharing a little bit about yourself and your background and what led you to MedTech. [00:01:45] Rick Sherak: Sure. Well, so I currently live just outside of Philadelphia with my wife and our four dogs. We just recently moved here from Boston, so we've had to quickly become Philadelphia Eagles fans. Go birds. We love it here. And my background is kind of interesting, a little bit diverse. I started off my career as an Air Force officer. I tried to follow my dad in his fighter pilot footsteps. Got almost there, but I had a medical disqualification, so I had to do a land based job, but really enjoyed the Air Force. It was a great way to pay for my college and to serve my country and also to learn leadership. It was like a masterclass in leadership. Talking about getting thrown into the leadership fire, and as a young 22 year old, lead a group of people on a mission, motivate everyone, and get everyone producing at their highest capacity. So that was a great way to start. But after I got out of the Air Force, I really wanted to go back to my roots, and that's in the sciences. I've always loved the sciences, especially the biological sciences. I have a degree in biological science from Baylor University. So out of the military, I was looking for an opportunity to use my interest in something that would support my family. So I started with Abbott Laboratories. And Abbott Laboratories, back in the day, was a Fortune 100 company, one of the up and coming medtech companies, had a pharmaceutical arm, but I belonged to the medical diagnostics side of it. And it was great. They, at the time, were hiring a bunch of ex military officers to be their field sales people and none of us knew how to sell. We were all out of either the Air Force, Army, Navy or Marines, but we learned quick. We understood, you know, there's the hill we have to take, but I really respected Abbott because they trained us not only how to sell, but how to sell with integrity, right? And they also, you know, they had 200 products that we had to learn and become masters at because we were selling to hospitals and medical laboratory clinicians, etcetera. But it was a great way to start my career, and I truly found that I loved it. One, I enjoyed the sales aspect. It was fun helping people solve problems with our products, and ultimately, help the patients get the best care right from their diagnostics. But two, it also taught me that I was pretty good at it. I did very well at Abbott. I promoted several times and won some national awards. And as a result, I was recruited away by another medtech company, which was a early stage organization called Ventana Medical Systems. I intended to be there for three years and learn everything I could and then expand my career. I was there for 15 years. And we had a ball. We took this little medical diagnostic company that came up with a transformative device that would automate very complicated processes in the pathology laboratory environment. So it was disruptive technology. We were going out there with something no one had ever seen before. And I joined them pre IPO. So we went public and then we started churning and burning and impressing Wall Street every quarter so that we can up our value. 15 short years later we sold the company to Roche Diagnostics. So what a great exit and just a wonderful experience and developing my leadership cause I was management as I quickly was filling levels as we were growing. But what a wonderful ride, that's something to see, somebody with an early vision to take it step by step to a wonderful exit. But we helped a lot of people, we became a market leader in immunohistochemistry automation, and it just truly was a great experience. But after Ventana, I wanted to do something a little different. So I stepped into the world of startups. I spent about 12 years in the startup world, worked for four startups, two of which died, which happens a lot in that environment. And then the other couple did pretty well. I really enjoyed it because now I was helping people on the oncology diagnostic side of medtech. So each startup had a unique laboratory technology that would better predict the patient outcome to a particular chemotherapy or targeted immunotherapy for their cancer. So, the whole purpose was to see how can we get better predictive value so that these patients don't have to suffer unnecessarily with the wrong drug. So that, again, was just a wonderful opportunity for me because more than not, I would come into these startups and have to create the commercial organization from scratch. That means I had to hire my own national sales team, my own marketing team, my own customer service team and logistics team to handle very delicate samples. But I loved it. It, it enabled me to take everything I learned from the air force, from Abbott, from Ventana and apply it to a small company environment. And I found that it was addictive, and that's why I stayed in it for many years. But then I did another turn and I took a sidestep because I loved also, has always been kind of a frustrated engineer. I joined an engineering company that just focused on design development of medical devices, and they hired me because of my diagnostic domain experience. And I went out and found early stage companies and brought them to this engineering firm so we could take the novel technologies from these companies and make them into a product that could be commercialized. So I did that for several years. Long story short today, I'm in a completely different type of medical device environment. I'm the CEO of Exokinetics, and Exokinetics is a very unique organization in that we decided to look at the mobility device market and fill the gap, because unfortunately people with mobility challenges are basically regulated to either wheelchairs or walkers or electronic scooters, all of which have significant problems to their health because they're not using their body in many cases. And fall prevalence-- people with walkers-- oh, it's just such a shame. There's over 50, 000 emergency room visits a year of people falling with their walkers. So anyways, Exokinetics has developed a very unique mobility device that gives people a lot more freedom. and safety in their daily challenges with mobility. So, sorry, it's kind of long. [00:08:44] Lindsey Dinneen: Oh, I loved it. No, I so appreciate it. Thank you for talking us through all of that. That was great. And so many questions, but I'll try to start at the end a little bit and then probably work my way back. But yeah, so, okay. So I'd love to hear more about the company that you are now involved in and this device. But I'd love to take it back a little bit further and say, what made you aware of this challenge existing that there isn't a great solution in the marketplace, or not maybe more updated options. So what made you aware of that challenge and then decide, "Okay, I think I have the tools, resources, ideas to fix it, to address it"? [00:09:25] Rick Sherak: It's a great question. I, one, I was not aware, right? I was not aware of the challenges. However, a buddy of mine, we go to the same church, you know, we're in a men's group, we're a bunch of old guys hanging out talking about stuff. And he was doing some investment investing into early stage or startup medical diagnostic companies. A very generous individual, and he knew of my background and he goes, "Rick," he goes, "I'm looking at this company. I'm not sure I want to invest, but maybe you can look at it with me." So I did some free consulting for him, he's my friend. And then he kept dragging me to this company to their board meetings. Right. And I'm going, "Hey, this is great," and I give him my advice because, because it was new for me. And that's how I found out, Lindsey, about the challenges that people with mobility issues have, is that the status quo now is, oh, you have Parkinson's, or you have cerebral palsy, or you've had a stroke. Put those people in a wheelchair and just let them live their life at that level. And I didn't realize how horrible that is for many of these people because they still have utility of their legs, right? But when you're confined to a wheelchair for long term, your legs will naturally atrophy, right? And become so weak that they won't be able to use them anymore. So what struck me, as mission driven, was that this company invented with their own engineers, this device that not only promotes people with mobility issues to use their body, but to use their body effectively moving around horizontally around the world, but also vertically. It enables them to go from a seated position to a standing position. And for us, for you and I, we're thinking, "Well, yeah that's pretty good." For them, that is a game changer being able to go from seated position to standing and then walk from that position all without the fear of falling. So, it really touched my heart as I learned more and more about the company and I kept giving more and more time to them. So eventually I was pulled aside and they said, "Rick, what's your appetite for running this company because we need to grow it and we need to get out there and help more people." So lo and behold, I've been here for almost a year. February 1st is my anniversary and it's been a great ride. I just love it. I have a passionate team, mostly of young people. I love it. I couldn't script better people, more compassionate, more caring. All of our customers are suffering in some way or another. Even our elderly customers that are just bad knees, bad hips, bad endurance, our device is perfect for them. So, yeah, you know, we're having fun. [00:12:27] Lindsey Dinneen: That's great. Well, yeah. Thanks for sharing a little bit about that too. And so, as you've stepped into this leadership role that you weren't necessarily anticipating was your next right thing, what were some of the challenges? Because you've had an amazing career, and like you've said at the beginning, you were learning leadership skills all throughout and you've had many iterations of different ways of approaching medtech, with the industry. But now as CEO, that's another thing. And so I'm curious, how was that transition to step into this leadership role and take it on? [00:13:03] Rick Sherak: No. And it has been different in many ways, but it's also very similar in others, right? Because in my opinion, leadership, really the definition from my perspective is that a good leader motivates effectively a group of people, talented people, and usually very diverse group of people, pulls them all together to accomplish an overall mission or goal, right? And it's it. That's the part I wouldn't say that's easy about my job now as a CEO, but it's natural and I love motivating my people. I'm a big fan of management by walking around and I try to talk to all my employees at least every day or every other day just to see what's going on, not only in the business side of things, but also in their personal side of things. I, I assume that nobody's going to respect me unless I earn it. And, I just wanna make sure that I'm leading by example and I'm the guy that either gets to the office first or leaves the office last, just trying to make sure that I'm there for my people when they need me. What is different, Lindsey, is that I am struggling with delegation because I want to do it all myself, right? And I know better. It takes me a long time to dye this hair white because I'm not that old, but just know better. But it's a struggle because you have to allow others to get things done and especially in a small company like this. We were still very early stage. People are wearing a lot of hats and I just have to allow them to go and give them the best guidance I can and then press on to the next thing, right? [00:14:49] Lindsey Dinneen: Absolutely. So, it sounds like you've been very intentional building a company culture that reflects the values that you care about, of course, and also reflects compassion, because you mentioned, your customers, for instance, are all folks that are in a difficult, challenging place. So how do you feel the importance blends from really intentionally cultivating a culture that is this empathic, creative problem solving, just really good culture, it sounds like, to how that affects how you basically present to the world who you are. [00:15:28] Rick Sherak: Yeah, well, no, that's a great question. So where our challenge is that our customer base is so broad, right? And like you said, all of our customers in our DTC business-- that's about 40 percent of our business is direct to consumer, right? But we have other customers, distributors. We have hospitals that use our device, physical therapy, occupational therapy, neurological research, you know, things like that. But the key, I think, from our perspective, is we want people to realize that, hey, we don't have 20 products, right, that we've gotten from other folks. We have designed and developed a very new and transformative device that only came about because we had our own internal engineers, and we've listened to what is needed out there to help people live a better, more free, more independent and active lifestyle. So, you know, interestingly, when we broadcast ourselves out there, I hope that people realize that, "Wow, this is not just a company selling something new, they design and develop this with their own people," right? There's a lot of love in our products, and people can tell because each one of our products is handmade, and it's customized to the individual ordering it by their weight, how much they weigh, and how tall they are, so we can adjust everything for them. And I tell you it's a lot of fun because some people literally take the time when they get their Zeen-- that's the name of our product, Zeen-- but they'll write us these wonderful notes on how this device has just transformed the way that they engage with their world. And, when you sit back and you go, "Hey, what difference are we making today?" Wow. That's why I think I have such a motivated group of people because every day we're talking to these wonderful, courageous individuals that have lost a big part of their ability to live effectively in the world and they're looking for something new, something meaningful and something that's going to help them. And when we can provide that it's just wonderful, very rewarding. [00:17:52] Lindsey Dinneen: Yeah. Yeah. Of course. Just to know the impact that you're making and able to make. And so the days that get really tough or frustrating or whatever, you can still hold onto this anchor of, "But we're making a difference. We know that." [00:18:07] Rick Sherak: And we see it. We have visitors come to the factory just about every week. Maybe two or three visitors will come and they'll try it out. Try out the Zeen to say, "Hey, I saw it on social media, just want to try it. You guys are local." And that's when we really get that, that visceral customer experience, right? It's just crazy, Lindsey. I've seen people come in, bent over sitting on this little electric scooter with a joystick. And they come in and they just look broken, right? And then we get them into a Zeen, and then they're all of a sudden their spine starting to straighten, right? They start sitting up, and then we slowly and compassionately show them how the device works and everything, but we make sure that they feel safe and that they trust. And as soon as we get that go ahead, which often you just see it in their eyes, then we'll engage the levers and the Zeen will lift that person with-- it's kind of like a big bicycle seat under them. It lifts up with this non motorized lift mechanism, that we invented, up to 75 percent of a person's body weight. So now they go from the seating position to standing. Now, many of these people can't do that on their own. They can't extend their legs from seating to standing. They need other people to grab them and lift them, right? But now Zeen lifts them. Now they're standing. And again, it's just phenomenal because this person that came in on this scooter bent over is now standing. They're putting weight on their legs. They're stimulating their brain because there's weight on their legs. Right now, neural connections are starting to flow again, and their spine straightens, and they stand tall, and when they take those first steps, often it's very slow, just tiny little steps. But then we just leave them be, and we talk to their family that came with them, and we go get something to drink, get some snacks, start chatting, and just let them be. And it's amazing, you can just see their brains working, and their legs moving faster and faster. I've seen people barely moving at the beginning, and at the end, they're cruising, we call it the lap, they go around the office, around all the desks and everything, and everybody's clapping, you know. It's amazing. [00:20:28] Lindsey Dinneen: Wow. [00:20:28] Rick Sherak: It's so cool! I'm not trying to overstate it, but this is our daily life. So I'm just very happy and pleased that my background has led me here. It's a great way to finish my career. I want to stay here for as long as I can. Hopefully it'll be many years because I enjoy every day of it. [00:20:52] Lindsey Dinneen: Wow. That's incredible. Yeah, and thank you for sharing those stories. I was just imagining that, that laugh and how amazing. [00:21:00] Rick Sherak: It is so cool. [00:21:03] Lindsey Dinneen: Can't possibly get old. Just witnessing joy and hope, honestly, even hope alone is... [00:21:10] Rick Sherak: One of the best is this father comes in with his twin boys. And the boys have cerebral palsy. It's a disease that you get from birth, right? And their legs are just not good. They have no balance at all. And the father brings them in. He carries them because they don't even have a mobility device that really works for them, except for walkers, like an old person walker, right? But he carries them in, he puts them on the, in the lobby, and we bring over the Zeens, and these little boys are the cutest things you've ever seen. They're just, they're twins, they're chatty, they're so excited. We get them into the device, and their first few steps, it's like I said before, we're just tiny, tiny. But then they built their trust. And at the end of the visit, these boys were running. I mean, they were digging in with their little legs, fully supported, fully trusting the device and their hands were in the air waving. And their dad is just like tears. He's just like gushing. He's going, "One, I've never seen my sons run before. Two, they've never moved without their hands either holding a walker or crawling on the floor." He goes, "These boys are running around with their hands in there in the air." And they're saying, "Hey, look, Daddy, my hands are in the air. I don't need to use my hands." Of course, we have Kleenex boxes all over the office. [00:22:36] Lindsey Dinneen: Yeah. I'm pretty sure you'd have to, it's just part of the the office supplies. [00:22:42] Rick Sherak: Exactly. Yeah. We have a Costco membership for regular shipment of Kleenex. Yeah. [00:22:49] Lindsey Dinneen: That's amazing. Oh, thank you so much for sharing that story. That's incredible... [00:22:53] Rick Sherak: Oh, yeah. [00:22:54] Lindsey Dinneen: ...just for a father's heart. [00:22:56] Rick Sherak: Oh, it's just so amazing. Yeah, it's so amazing. [00:23:00] Lindsey Dinneen: So this is all incredibly exciting just the way it is right now, but I imagine there are future plans. Can you share a little bit about what's next? What are you excited about as you move forward? [00:23:12] Rick Sherak: Well, what's really exciting is our growth potential, right? So again, the Zeen is a very unique device, but it fits so many different segments of populations. Like we've been talking about people with chronic illness. That is our core group, right? We work with people with Parkinson's, MS, muscular dystrophy, cerebral palsy, ataxia, you know, just about anything like that where people have strength, balance, or endurance issues. The other part that we're really excited about this year is that we didn't realize until those boys, how much our Zeen would help in the pediatric environment. So now we're making a very concerted effort going after the children's hospital physical therapy groups, showing them the amazing utility of a Zeen. And also because it's so adjustable, a person, a child can get into a Zeen early, let's say at the age of seven, and it could actually stay and grow with them until they're 14 or 15 years old. The whole thing adjusts up. So we're very excited about that market space. And we're also introducing the Zeen to luxury senior centers, because so many of our Zeen customers are just elderly people that don't want to give up, that have this incredible determination to either maintain or regain their mobility. Their knees hurt, their hips hurt, their endurance is down. So that's another avenue that we're introducing ourselves to, primarily through social media and publications through PR. But we're hoping this new awareness will get more Zeens out there. Our goal is really awareness. And that's one of the reasons that you and I are talking. I want to get out there as much as possible and let people know that there's other alternatives out there for their loved ones or for themselves if they have mobility challenges. And please check us out. We have a really cool website, a lot of videos, a lot of testimonials, and we just love helping people. And we're very fair in business. Our product is not cheap, but we give most customers a 14 day minimum home trial, and we say, "Use it a lot, as much as you can to make sure it's a good fit." If you don't like it, money back. So we try to be as fair as possible to make sure it's a good fit. [00:25:39] Lindsey Dinneen: Yeah, that sounds good. Yeah. And so for any of our listeners that are, you know, going to go and check out the website, just make sure you have your own stash of Kleenex. Oh man. [00:25:54] Rick Sherak: And every time we sell a Zeen, it comes with a virtual training session. So it's a one on one with one of my specialists. And I tell you, these folks are the best. So the best trainers and they're just the most delightful people, right? And they're like you. They're virtual, but you feel like they're right there with you. So we do virtual training for every one of our customers. And, it gives us that opportunity to see people eye to eye and to ensure that they understand their new tool and how to use it and how to, like I mentioned before, how to trust it, and realize that they're not going to fall, that they can move again, and they can do it safely. [00:26:34] Lindsey Dinneen: Amazing. Well, gosh, thank you so much for sharing about the company and... [00:26:38] Rick Sherak: Yeah. [00:26:39] Lindsey Dinneen: ...the device and the lives that it's impacting. And I just, I love learning about this. I'm so excited about the work that you're doing. So thank you for putting in the work. It's not easy. Startup world is difficult and especially medtech, but you've done it. So good job. [00:26:56] Rick Sherak: Well, and this is also interesting for me because it's manufacturing. Before, I didn't have to manage manufacturing. So manufacturing is a whole different beast with getting your parts, getting them ordered in time 'cause everything has to be built just right. This is like a high end super bike, you know, has the latest in technology for aluminum framing and engineering leverage. So that's a challenge for sure. But the other thing I wanted to plug real quick, Lindsey, if you don't mind, is again, we're a premium priced product, but we're not covered under insurance plans right now. That means Medicare or Medicaid. So, part of our outreach is we've created a foundation. It's a nonprofit foundation so that if we can find donors that want to support, the money goes into our foundation, and we take applicants and we provide grants for up to half the cost of a Zeen through the foundation. The other half is on the people that are trying to buy it. And, it's so interesting. Talking about putting skin in the game, right? People call and say, "Geez, I just can't swing that amount of money." Well, let's talk about the foundation, but you have to come up with half. And that creates such a-- it's such a partnership, and they're so excited. They'll be emailing my folks going, "Hey, I was able to raise 500 through a crowdfund! I just got to keep going!" And we're going, "Yeah, keep going!" And as soon as we hit that halfway mark, the foundation kicks in and covers it. So again, I just want to put a plug out there so that we can help very deserving people that just financially need a little support. Yeah. [00:28:37] Lindsey Dinneen: I love that. So that's a great way for even listeners to get involved, even if they don't necessarily personally need the device, but donating to this incredible cause, that would be awesome too. [00:28:48] Rick Sherak: Anything would be so appreciated. [00:28:50] Lindsey Dinneen: Great. Yes, absolutely. Well, okay. So pivoting the conversation a little bit just for fun. Imagine that you were to be offered a million dollars to teach a master class on anything you want. It can be within your industry currently, it could be about anything. What would you choose to teach? [00:29:13] Rick Sherak: You know, that's funny that you said that. I live right next to Villanova University, and a lot of my neighbors are professors there. And one of our best friends that lives a few houses down she's in the business ethics department. And she even said, she goes, "Rick, have you ever thought about teaching?" And I said, "You know, I've never really been a teacher." But if I were to teach, the thing I would love to do would be to capture over all these years of me being in this industry, the nuances of the psychology of sales. Because people think of sales as, "Oh, you're trying to trick people into buying, right?" Turn that completely upside down to, you're trying to assist people to buy. Because people really, when they're looking at your product, they want it. But they need help. They're counting on you to help them in that process. And it's a psychological bond when you're talking to somebody and you have a product and they have a need and you're trying to find that, that perfect combination, right? So that they feel, "Hey, this is great for me. It's worth every penny because I see the value." Versus having them feel, "Oh man, I'm going to get ripped off." So I would love to go down that path. I think that's so interesting because people are people, and salespeople, the best ones I've ever seen, like I mentioned before, are compassionate and caring, but they're also pleasantly persistent, right? And they just, they go, they listen and they say, "All right, but let's keep moving down the path." And people that are on the buying side truly want that. They want that partnership, that walking side by side down that path to purchase, because sometimes they're not courageous enough to buy just by themselves. So, to destigmatize sales would be kind of fun. [00:31:13] Lindsey Dinneen: I love that. That would be great. That'd be a great masterclass too, just to really dive into some of that, and yeah, to put a different perspective on your role and you're helping somebody to achieve what their goals are, to be honest. [00:31:26] Rick Sherak: Absolutely. [00:31:27] Lindsey Dinneen: I love that. [00:31:28] Rick Sherak: Absolutely. And we've all had those good experiences, and we've all had those bad experiences. [00:31:32] Lindsey Dinneen: Definitely. Definitely. So how do you wish to be remembered after you leave this world? [00:31:40] Rick Sherak: You know, that, that's interesting because I love to read. My morning time is my reading time. That's my time. It's me and my two collies. They're also early risers. The pugs, the two pugs, no, they'll sleep in with their mother. But in my reading and in my studies, essentially, I think it all boils down to at the end of the day, when the curtain starts coming down, wouldn't it be nice, when you're out, you're no longer here and people look back and they just say, "You know what? That guy or that lady really genuinely cared about other people." I think authenticity and being genuine is something I would love to be remembered for. And it's not easy, because sometimes you're not authentic to yourself, yet to others. [00:32:29] Lindsey Dinneen: Yeah. [00:32:32] Rick Sherak: But especially at this stage in my life, I just see caring for people is just amazing. Talking about, if everybody cared a little bit more for each other, it might be a different place. [00:32:43] Lindsey Dinneen: Yeah. And having the courage to be authentic and honest can sometimes also be, it does come with a little bit of vulnerability. So I love that. [00:32:55] Rick Sherak: Oh yeah. Oh my gosh. You know, it's all about, if you're just so lucky to have a little bit of grace, a little bit of wisdom, but like you said, a lot of courage. That's when it all means something, right? Cool. Oh. [00:33:10] Lindsey Dinneen: I know. What is one thing that makes you smile every time you see or think about it? [00:33:22] Rick Sherak: Well, you know, funny because we've been talking about leadership and sales. I just got to tell you a quick story because it always makes me smile. As I mentioned before, I was an Air Force officer and all of a sudden I jump out of the Air Force into a sales role with a medical diagnostic company. And, I just went through training. I got assigned to my territory. Baton Rouge, Louisiana. I'm a Colorado boy. So Baton Rouge, Louisiana was a little bit different for me, but the company moved me down there, and I started my sales career. And my, my customers were all hospitals and clinical laboratories in Baton Rouge, Lafayette, and the Bayou South, all those little towns in there. And I didn't realize it until after I started, but my territory was made out of the accounts the other sales people didn't want. [00:34:16] Lindsey Dinneen: Oh. [00:34:17] Rick Sherak: So the guys that were there, they cherry pick the good accounts, and the ones they didn't want, they made into my territory, right? The new guy. But I went in, I was dialed in. I had my brochures. I knew all my product knowledge. And I'd make appointments and I'd sit in front of these lab managers and these clinical influencers. And these lovely people, they would sit there. They would be so kind. They'd have their arms crossed. I go through my spiel and then they just look at me and they say, "Thank you, Rick, for coming. I'm not interested at this time." I go, "Okay." So this went on, Lindsey, for six months at every single hospital or clinical laboratory. I was like on the bottom of the sales list. I couldn't get anybody to buy anything. And it was like, it was so funny. And this is what makes me laugh. I'll never forget. I was down in south of Lafayette, and I was sitting in front of this lab manager and I've seen him every three weeks like clock work, right? And I'd always bring in new information, recap what we discussed before, and asked for the business. And he'd always say, "No, I'm not interested." But about six months in, he just looked at me and I got through my spiel. And he goes, "Rick," he goes, "Are you just going to keep showing up every three weeks?" And I said, "Yes, sir." And he says, "Look," and I mean, he's going, "Well, I'm not buying anything from you." And I said, "Yes, sir. But I, I truly feel that my products are the best products that you could use in your laboratory to make you more successful and to give your patients the best diagnostic information to help them fight their disease." Because it was mostly oncology focused. And he just looked at me and he goes, "You truly believe that?" I said, "Yes sir, I truly believe and I'm going to keep coming back until you believe." And he just sits back and he, I'll never forget this, he unfolded his arms, put his hands on the table and he goes, "Well, okay, then let me see what you got." And it was awesome. Lindsey, I swear there was like some underground communication channel because every hospital or clinical laboratory started listening to me after about six months. It was weird. And then another six months, I was on top of the sales rolls, and I had turned my territory around and we were just having a ball. But it was that persistence, it was just in the caring. I just cared. I was convinced my products were better, and he appreciated that. And, it, it was a fun, it makes me smile today because there's nothing like seeing somebody say, "Well, you know what, I trust you enough to listen to you now." [00:37:06] Lindsey Dinneen: Yeah. Wow, that's awesome. They really had to go through that know, like, and trust you cycle or a journey. [00:37:15] Rick Sherak: These are long term Louisianians. I'm coming in as an outsider, too. So that was, I had to prove myself. But they are the one most wonderful people. Before I got promoted out of that territory, I used to show up at least once every, maybe two months, per hospital with all these crawfish and a big old pot and a boiler and I would be out in the parking lot. I'd be boiling crawfish and I called the lab and I'd say, "Hey guys, I got crawfish!" And they go, "Oh, Rick has crawfish!" And they all come out and we'd all eat crawfish. That's how you do it in Louisiana. It was a good time. [00:37:54] Lindsey Dinneen: Very cool. Thank you. Thank you so much for sharing about that. And just in general, being so willing to share so much of your story. I really appreciate it. I loved getting an opportunity to learn about you and your background and your heart for MedTech, your heart for the people that you're serving. So thank you. I know days aren't always a walk in the park as much fun as I know you're having, but I know you have good days and bad days. So thank you again so much for joining me. [00:38:19] Rick Sherak: Thank you, Lindsey. [00:38:20] Lindsey Dinneen: And I just wish you the most continued success as you continue to work to change lives for a better world. And just also thanks to our listeners for tuning in. And if you're feeling as inspired as I am, I'd love it if you'd share this episode with a colleague or two and we'll catch you next time. [00:38:40] Ben Trombold: The Leading Difference is brought to you by Velentium. Velentium is a full-service CDMO with 100% in-house capability to design, develop, and manufacture medical devices from class two wearables to class three active implantable medical devices. Velentium specializes in active implantables, leads, programmers, and accessories across a wide range of indications, such as neuromodulation, deep brain stimulation, cardiac management, and diabetes management. Velentium's core competencies include electrical, firmware, and mechanical design, mobile apps, embedded cybersecurity, human factors and usability, automated test systems, systems engineering, and contract manufacturing. Velentium works with clients worldwide, from startups seeking funding to established Fortune 100 companies. Visit velentium.com to explore your next step in medical device development.

In this episode of Medsider Radio, we sat down with Randy Pritchard and Erica Rogers, leaders of Axena Health. Axena is transforming pelvic floor therapy with Leva, a device bringing clinically-proven, supervised pelvic floor muscle training into women's homes. Randy, CEO of Axena, brings nearly 25 years of healthcare experience to the company, most recently as CEO of Pillar Biosciences and previously holding leadership positions at Roche Diagnostics, where he spent 18 years developing commercial expertise. Erica, who sits on Axena's Board of Directors, spent a decade as President and CEO of Silk Road Medical, leading the company from early clinical trials through IPO and eventual acquisition by Boston Scientific. A returning guest to the podcast after nearly half a decade, Erica previously held roles at Medicine360, co-founded two other medical device companies, and spent over 12 years at Boston Scientific prior to her role at Silk Road.In this interview, they share essential medtech commercialization insights: identify your specific patient segment, build continuous clinical evidence, and communicate consistently with investors. Their experience offers invaluable lessons for medical device entrepreneurs navigating today's complex healthcare landscape.Before we dive into the discussion, I wanted to mention a few things:First, if you're into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You'll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and 3 packages that will help you make use of our database of 750+ life science investors more efficiently for your fundraise and help you discover your next medical device or health technology investor!In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the latest Medsider Mentors Volume VII. If you're interested, go to medsider.com/subscribe to learn more.Lastly, if you'd rather read than listen, here's a link to the full interview with Randy Pritchard and Erica Rogers.

AJ Jones II is back full-time in Washington, DC, with a new job leading communications for Monumental Sports & Entertainment, the owner of the NBA's Washington Wizards, the NHL's Washington Capitals, the WNBA's Washington Mystics and other sports brands. Jones talks about making the transition to the sports world from Starbucks, where he was EVP and chief corporate affairs officer and previously EVP and chief communications and public affairs officer. There's no shortage of other news coming out of Washington, DC, including Wednesday's major tariff announcements and significant job cuts across communications teams in the Department of Health and Human Services. Jones also offers his two cents on the biggest marketing and communications news of the week, including April Fools' Day campaigns and major people moves at Andreessen Horowitz and Roche Diagnostics.  Follow us: @PRWeekUSReceive the latest industry news, insights, and special reports. Start Your Free 1-Month Trial Subscription To PRWeek

Episode #168 with Dr Allan Pamba, Executive Vice President at Roche Diagnostics. Dr Allan Pamba is a global health leader and seasoned executive at the forefront of transforming healthcare systems through innovation, access, and sustainability. As Executive Vice President at Roche Diagnostics, the world's largest biotech company and a global pioneer in personalised healthcare, he brings decades of experience bridging the worlds of science, policy, and development to improve lives across Africa and beyond.In this episode, we dive into the urgent call for Africa to rethink its healthcare financing strategy, particularly around diagnostics amid shifting global policies and the threat of reduced foreign aid. With just five years left to meet the Abuja Declaration's 15% health budget commitment, Dr Pamba offers sharp insight into what it will take for African nations to move from dependency to self-reliance.What We Discuss With Dr AllanWhy do diagnostics, despite influencing 70% of clinical decisions, receive only 2% of healthcare funding in Africa?The potential impact of U.S. foreign policy shifts, including a possible return of the Global Gag Rule.How Africa can leverage economies of scale, pooled procurement, and regional collaboration to lower the cost of diagnostics.Ways African governments can create more attractive environments for private sector investment in diagnostics and healthcare infrastructure.Innovative financing models, public-private partnerships, and redefining government's role in health delivery.Did you miss my previous episode where I discuss Why the West Isn't Always Best: How Afro-Optimism Can Redefine African Success? Make sure to check it out!Like this show? Please leave us a review here -- even one sentence helps!Connect with Terser:LinkedIn - Terser AdamuInstagram - unlockingafricaTwitter (X) - @TerserAdamuConnect with Dr. Allan:LinkedIn - Dr Allan PambaTwitter (X) - @RocheDo you want to do business in Africa? Explore the vast business opportunities in African markets and increase your success with ETK Group. Connect with us at www.etkgroup.co.uk or reach out via email at info@etkgroup.co.ukSubscribe to our newsletter for exclusive content, behind-the-scenes insights, and bonus material - Unlocking Africa Newsletter

Herzlich willkommen zu einer neuen Folge des BB RADIO Mitternachtstalk-Podcasts! Ich bin Jens Herrmann, euer Gastgeber, und heute habe ich eine Frau zu Gast, die nicht nur die Finanzwelt aufmischt, sondern auch als inspirierendes Vorbild gilt: Dr. Carmen Mayer. Sie ist promovierte Biochemikerin und zählt zu den erfolgreichsten Börsenexpertinnen Deutschlands.Mit ihrem Unternehmen für Aktiencoaching hat sie es in kürzester Zeit an die Spitze der Branche geschafft. Ihr persönliches Portfolio? Ein siebenstelliges Depot und zwei Häuser im idyllischen Allgäu. Ihr Weg begann mit einem Biologiestudium an der Heinrich-Heine-Universität Düsseldorf und in Breslau, das sie mit Bestnoten abschloss. Anschließend promovierte sie in Chemie an der Technischen Universität München mit magna cum laude. Von 2011 bis 2016 arbeitete sie bei Roche Diagnostics, einem globalen Pharmakonzern. Doch während ihrer Elternzeit als zweifache Mutter entdeckte sie 2017 ihre Leidenschaft für die Börse. Als Autodidaktin eignete sie sich umfassendes Wissen über Aktien und Investitionen an. 2019 startete sie den Podcast "Mami goes Millionär – Der Aktien-Podcast" und gründete 2020 ihr eigenes Unternehmen für Aktiencoaching. Seitdem ist sie eine gefragte Expertin für Börseninvestitionen. Ihr Buch "Mami goes Millionär – Ich verdiene meine Millionen selbst" wurde zum Spiegel-Bestseller. Carmen Mayer richtet sich vor allem an Frauen, ermutigt aber auch Männer, ihre Finanzen selbst in die Hand zu nehmen. Ihr Ziel: Wissen vermitteln und ein positives Mindset fördern. Sie zeigt, dass finanzielle Unabhängigkeit auch ohne kompliziertes Fachwissen, teure Berater oder endlose Recherche möglich ist. Eine spannende Geschichte einer Selfmade-Millionärin, die andere an ihrem Erfolg teilhaben lässt.Freut euch auf ein inspirierendes Gespräch mit Dr. Carmen Mayer – einer unterhaltsamen und klugen Frau, der man gerne zuhört. Ein Talk, der euch einen neuen Blick auf eure Finanzen eröffnen wird!

Sexuell übertragbare Infektionen (STI) sind Infektionen, die in den meisten Fällen durch sexuelle Aktivitäten oder ungeschützten Geschlechtsverkehr übertragen werden. Dabei können STIs durch eine Vielzahl von Pathogenen, wie Bakterien, Viren, Pilzen aber auch Parasiten, verursacht werden.

In this episode, Dr. Vishakha Sharma, Senior Principal Data Scientist at Roche Diagnostics shares her perspectives on the potential of GenAI to improve patient outcomes, enhance the efficiency of healthcare delivery, and reduce costs. She also addresses some of the key issues surrounding data interoperability and data integration when dealing with diverse data sources and unstructured data. The discussion brings attention to the need for guiding principles and highlights the ethical frameworks.Host: Michaela Miller, Practice Lead, U.S. MedTech Technology & Analytics, IQVIAFeatured Speaker: Vishakha Sharma, Ph.D., Senior Principal Data Scientist, Roche Diagnostics

This episode is a discussion of the paper entitled, "Catheter Ablation versus Advanced Therapy for Patients with Severe Heart Failure and Ventricular Electrical Storm." https://www.hrsonline.org/education/TheLead https://doi.org/10.1016/j.hrthm.2024.09.045 Host Disclosure(s): W.Sauer: Honoraria/Speaking/Consulting: Biotronik, Biosense Webster, Inc., Abbott, Boston Scientific, Research: Medtronic   Contributor Disclosure(s): R. Kerley: Nothing to disclose. A. Desai: Research: Novartis, Bayer Healthcare Pharmaceuticals, Abbott Medical, AstraZeneca, Honoraria/Speaking/Consulting: Novartis, Abbott, AstraZeneca, Regerneron, Alnylam Pharmaceuticals, Bayer Healthcare Pharmaceutricals, Cytokinetics, AxonTherapies, Avidity Biosciences, Medpace, Merck, New Amsterdam Pharma, Parexel, Roche Diagnostics, GlacoSmithKline, NovoNordisk, Veristat, Verily/Google, Zydus, River2Renal, Membership on Advisory Committees: BioFourmis

Gebärmutterhalskrebs ist weltweit die vierthäufigste Krebserkrankung bei Frauen. Sie wird zu 99% der Fälle von Humanen Papillomviren (HPV) und zu rund 70% von den beiden Hochrisiko-Typen HPV 16 und 18 ausgelöst. Durch eine Diagnostik im Rahmen des Gebärmutterhalskrebs-Screenings können Krebsvorstufen und frühe Erkrankungsstadien jedoch rechtzeitig erkannt und behandelt werden. Die Früherkennung von Gebärmutterhalskrebs basiert dabei auf zwei Säulen: dem Pap-Test für Frauen bis 34 Jahre und der Kombination aus Pap- und HPV-Test für Frauen ab 35 Jahre.

ESC TV Today brings you concise analysis from the world's leading experts, so you can stay on top of what's happening in your field quickly. This episode covers: Cardiology This Week: A concise summary of recent studies Which MRA to use in which heart failure patient Managing electrical storm Mythbusters: garlic protects from the heart Host: Perry Elliott Guests: Carlos Aguiar, Sana Al-Khatib, Rudolf de Boer Want to watch that episode? Go to: https://esc365.escardio.org/event/1792 Disclaimer ESC TV Today is supported by Bristol Myers Squibb. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsor. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests Stephan Achenbach, Sana Al-Khatib and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Sanofi Aventis, Novo Nordisk, Terumo. Rudolf de Boer has declared to have potential conflicts of interest to report: direct research funding from European Research Council (ERC), Netherlands Heart Foundation, Fondation leDucq, Netherlands Organization for Scientific Research. Research funding to department or institution: AstraZeneca, Abbott, Boehringer Ingelheim, Cardior Pharmaceuticals GmbH, NovoNordisk. Direct fees from Abbott, AstraZeneca, Cardior Pharmaceuticals GmbH, NovoNordisk, Roche Diagnostics. Fees to department or institution: NovoNordisk. Perry Elliott has declared to have potential conflicts of interest to report: consultancies for Pfizer, BMS, Cytokinetics, AstraZeneca, Forbion. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc., Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Maken chips in en rond ons lijf ons gezonder? VRT NWS-journalist Tim Verheyden testte de gezondheidsring van Samsung. Tamara Denie van Roche Diagnostics vertelt over hun sensoren bij diabetespatiënten. Dave Allegaert uit Waregem kreeg een handgeschreven verjaardagskaart in de bus van een lokale N-VA-kandidaat. Maar Dave kent de politicus van haar noch pluim en vindt dit heel eng. Hoe kan dit? Privacy-expert Bart van Buitenen (Dasprive vzw) legt uit wat er gebeurd is.

Enterprise Ireland, in collaboration with Roche Diagnostics UK and Ireland, is delighted to launch the Incubator Programme for 2024 which will support the growth of a number of companies developing healthcare solutions that will impact patient care in the field of diagnostics. The programme builds on the success of the 2022 programme to support Irish start-ups and SMEs in the field of diagnostic technology. Five Irish start-ups and spin-out companies offering disruptive diagnostic innovations to the healthcare sector will participate in the 2024 programme. The nine-month programme features a wide range of masterclasses that focus on equipping the participants with the experience and knowledge needed to succeed. Topics include patient pathways and customer needs, evidence generation, accessing international markets, the founders' mindset, and the emerging digital space. The programme taps into market-leading expertise in commercialising diagnostics and as part of the schedule, the participants will have the opportunity to visit Serosep's laboratory diagnostic manufacturing site to learn first-hand what is involved in the operation of a world leading testing facility. Commenting on the 2024 programme, Finbarr Kenny, Director of Ireland & Director of Sales and Account Management at Roche Diagnostics said, "Roche has a rich heritage of working with Irish-owned companies with whom we partner to provide diagnostic solutions to patients within the Irish healthcare system. "We recognise the critical role that Enterprise Ireland plays in supporting start-up companies in accelerating innovations that address current and future unmet needs, not just in Ireland but globally. We are excited to share our expertise with Irish start-up companies. The mentoring programme aligns with our social value commitment to support local economic growth and skill development." Cepta Duffy, Department Manager, Industry & Lifesciences High Potential Start-Ups, Enterprise Ireland said, "Enterprise Ireland's mission is to support the ambition of Irish entrepreneurs to help them scale globally. We are delighted to partner with Roche Diagnostics once again to support the Incubator programme, which will help start-ups in the field of diagnostics to learn and gain insights from other innovators and established businesses in their field on how to grow their business. The programme will equip companies developing world-class diagnostic solutions with the skills to bring their innovations to the next level and Enterprise Ireland looks forward to supporting them on their journey." See more stories here.

In this episode, Dr. Vishakha Sharma, Senior Principal Data Scientist at Roche Diagnostics, shares her perspectives on the potential of Generative AI (GenAI) to improve patient outcomes, enhance the efficiency of healthcare delivery, and reduce costs. She also addresses some of the key issues surrounding data interoperability and data integration when dealing with diverse data sources and unstructured data. The discussion brings attention to the need for guiding principles and highlights the ethical frameworks released by the World Health Organization. Host: Michaela Miller, Practice Lead, U.S. MedTech Technology & Analytics, IQVIAFeatured Speaker: Vishakha Sharma, Ph.D., Senior Principal Data Scientist, Roche Diagnostics

Less than 50% of the world's population have access to diagnostics, according to statistics from the medical journal, The Lancet.That drops to 20% when it comes to Africa, where the diagnostic gap is most severe at the level of primary health care. According to The Global Health Fund, Africa bears a quarter of the global disease burden and endures over 100 health emergencies a year.In this episode of the Africa Daily Podcast, Peter Musembi explores what needs to be done to address that acute gap in diagnostics in Africa.Guests: Zambian health worker Constance Mudenda and Dr Allan Pamba, Executive Vice President in charge of Africa for Roche Diagnostics.

Das Ziel der Gebärmutterhalskrebsvorsorge ist es, auffällige Zellen und Krebsvorstufen rechtzeitig und verlässlich zu erkennen. Werden beim Pap- oder dem HPV-Test Auffälligkeiten festgestellt, sind unter Umständen weitere Untersuchungen notwendig, um abzuklären, ob es sich tatsächlich um eine Krebserkrankung handelt. Welche Bedeutung Biomarker wie p16/Ki67 für die Früherkennung von Zervixkarzinomen und entsprechende Vorstufen haben, erklärt unser heutiger Gesprächspartner Dr. Gerd Böhmer.

Hitesh Dave is the Digital Pathology and AI Lead of Roche Diagnostics. Dr. Dave is a Global Change Leader, Chartered Scientist and Strategic management consultant. He will talk about how Roche is restructuring itself for the age of digital and computational pathology. The views shared or expressed here at the podcast are from Hitesh's experience only, and not necessarily represent anything from Roche.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Medtronic is focusing on prediction as the next frontier in heart disease management, utilizing artificial intelligence to reduce false positives in its insertable cardiac monitors. The company's cardiovascular diagnostics and services business leader emphasizes the time-saving benefits for clinicians. Additionally, diabetes device firm Embecta is considering a sale two years after spinning out of BD, while Dexcom shares have plunged due to a lower sales outlook. The FDA has sent warning letters to Chinese syringe manufacturers, and the top five medtech deals in the first half of 2024 include Johnson & Johnson's takeover of Shockwave Medical. Roche Diagnostics' base business has grown 9 percent in the first half of 2024, and Tricares has raised $50 million to trial a tricuspid heart valve replacement system.Sanofi's bet on immunology is starting to pay off, with analysts noting that the pipeline of immune system therapies is underappreciated by investors. Pfizer's hemophilia gene therapy has shown positive results in late-stage studies, but questions remain about long-term potential. A startup led by former J&J executives, Third Arc Bio, raised $165 million for cancer and immune disease drugs. The US government declined to clear Bluebird Fertility Support for Zynteglo patients, and the GLP-1 drug race is heating up as pharma companies compete in the obesity market. The biopharma industry is evolving rapidly, with advancements in cell therapy and personalized cancer treatments.Steward Health System failed to attract qualified bidders during the first round of hospital sales in Ohio and Pennsylvania. Humana's CenterWell will open 23 primary care clinics in Walmart stores, while CMS is cracking down on ACA brokers to prevent unauthorized plan switching. AI is being used to power clinical trials and improve patient answer rates in healthcare organizations. The text also highlights stories from other publications, including the challenges faced by hospitals in non-Medicaid expansion states and the impact of Medicaid on insurers during the pandemic.Dexcom shares plunged due to a lower sales outlook, Abbott recalled Freestyle Libre 3 sensors for incorrect glucose readings, and a study found that AI's expert-level image analysis can be flawed. Edwards spent $1.2 billion on 2 heart device firms, Inspire Medical's COO is leaving for a CEO role at another company. Abbott stated that the sensor recall may affect less than 1% of users in the U.S. Researchers discovered that AI can generate expert-level image analysis with flawed reasoning. Edwards reported a slowdown in its core business, causing share prices to drop.Bristol Myers had a strong week of pharma earnings, with all five large pharmaceutical companies reporting raised profit or revenue guidance. Roche plans to move quickly with differentiated obesity drugs. Leqembi was voted down by European regulators, but Eisai plans to appeal. Two biotechs cut staff, while Abbvie weathers biosimilar threats. Sanofi's immunology pipeline is starting to pay off. The pharma industry is racing to develop GLP-1 drugs for obesity treatment.Gilead's $4.3 billion acquisition of Cymabay Therapeutics will face a significant test next month when the FDA decides on their autoimmune disease drug, Seladelpar. The treatment targets primary biliary cholangitis, a liver disease with no cure. Positive interim results have shown improvements in liver injury markers and reduced inflammation. Similarly, Citius Pharmaceuticals awaits an FDA decision on their rare blood cancer drug, Lymphir, with CEO Leonard Mazur personally investing $22.5 million in the company.The text discusses various marketing campaigns and initiatives, including Hyundai's shift to more emotional advertising for the Summer Olympics, Palo Alto Networks equipping Keanu Reeves with AI-powered weapons for a

Johnny Smith, Vice President of Communications for Roche Diagnostics North America, shares how to create a strategic prioritization framework that meets communications and business objectives. He describes how his team uses a confidence-level scoring system to ensure they focus on projects that deliver the most impact. In our discussion, Johnny also talked in detail about the value of discipline in leadership.

In this bonus Q&A with Jennifer, she shares:Her proudest moment and biggest failure in her career so farA trend that she is following in Talent Development right nowThe biggest challenge she sees in Talent Development todayBooks that have made a big impact on her lifeOne piece of career advice she has for youJennifer is passionate about helping others be their best. For almost 25 years leaders at all levels have appreciated her candor & humor coupled with practical strategies for the care & feeding of other humans (you know, leadership). Jennifer pulls from a range of leadership concepts to create experiences to help teams deliver on their goals. It's been said Jennifer is allergic to inauthenticity. Jennifer earned a BS in Apparel Merchandising from Indiana University. That's right, the very common leadership development educational background of apparel and retail planning.Jennifer started her career with Target Corporation after attending in-person interviews. In January. In Minneapolis. During her tenure with Target she was asked to join the training team in support of the business analyst training program. It was in that role that she realized she is at her best when she is “business adjacent”- meaning enabling the people and teams delivering the profit. In 2012 she returned to Indiana and joined Roche Diagnostics.Over the next 8 years in leadership development and organizational development roles, Jennifer created a new leader program called Jumpstart, built a college grad new hire rotational program from scratch, and dove head first into the roll out of the Leadership Circle Profile 360 from The Full Circle Group. In mid-2020 Jennifer joined the leadership development team at Elevance Health (formerly known as Anthem) to help shape a reimagined leadership development portfolio. Over the last 18 months Jennifer has focused almost solely on the creation of two new high potential development programs, one for manager level leaders and one for those on an executive track.She is also a big believer in the concepts around Strengths Finder from Gallup (Communication, Individualization, Woo, Activator, Significance) and Multipliers from The Wiseman Group (Idea Guy!).She also was named Most Improved Handwriting in 1988 from Klondike Elementary School. Coming to work is a welcome respite for Jennifer who spends her personal time meeting the demands of an opinionated almost 7 year old daughter, Davis, & super needy dog, Holly. Occasionally Jennifer manages to convince herself to jump on her Peloton bike, but usually rewatching The West Wing wins out.Connect with Andy Storch:WebsiteLinkedInJoin us in the Talent Development Think Tank Community!Join us at the Talent Development Think Tank ConferenceConnect with Jennifer Butler:LinkedIn

Host Andy Storch sits down with Jennifer Butler, the director of leadership development at Elevance Health, to delve into the intricacies of creating comprehensive leadership programs. With over 25 years of experience in the field, Jennifer shares her insights on implementing effective leadership development initiatives, including live events, virtual sessions, and small group coaching.Together, they discuss:The structure of various developmental programs at Elevance Health, from manager-focused projects aimed at understanding the company's value chain to executive programs featuring one-on-one coaching and action learning projects. How these initiatives align with the company's diversity, equity, and inclusion mission, ensuring equal opportunities for leaders from diverse backgrounds.The importance of assessing program impact, leveraging assessment tools, and co-creating with partners to tailor leadership programs to business needs.Jennifer's unique career journey and valuable advice for those looking to thrive in talent development.Jennifer is passionate about helping others be their best. For almost 25 years leaders at all levels have appreciated her candor & humor coupled with practical strategies for the care & feeding of other humans (you know, leadership). Jennifer pulls from a range of leadership concepts to create experiences to help teams deliver on their goals. It's been said Jennifer is allergic to inauthenticity. Jennifer earned a BS in Apparel Merchandising from Indiana University. That's right, the very common leadership development educational background of apparel and retail planning.Jennifer started her career with Target Corporation after attending in-person interviews. In January. In Minneapolis. During her tenure with Target she was asked to join the training team in support of the business analyst training program. It was in that role that she realized she is at her best when she is “business adjacent”- meaning enabling the people and teams delivering the profit. In 2012 she returned to Indiana and joined Roche Diagnostics.Over the next 8 years in leadership development and organizational development roles, Jennifer created a new leader program called Jumpstart, built a college grad new hire rotational program from scratch, and dove head first into the roll out of the Leadership Circle Profile 360 from The Full Circle Group. In mid-2020 Jennifer joined the leadership development team at Elevance Health (formerly known as Anthem) to help shape a reimagined leadership development portfolio. Over the last 18 months Jennifer has focused almost solely on the creation of two new high potential development programs, one for manager level leaders and one for those on an executive track.She is also a big believer in the concepts around Strengths Finder from Gallup (Communication, Individualization, Woo, Activator, Significance) and Multipliers from The Wiseman Group (Idea Guy!).She also was named Most Improved Handwriting in 1988 from Klondike Elementary School. Coming to work is a welcome respite for Jennifer who spends her personal time meeting the demands of an opinionated almost 7 year old daughter, Davis, & super needy dog, Holly. Occasionally Jennifer manages to convince herself to jump on her Peloton bike, but usually rewatching The West Wing wins out.Connect with Andy Storch:WebsiteLinkedInJoin us in the Talent Development Think Tank Community!Join us at the Talent Development Think Tank...

Why you should listenLearn from Russ's extensive experience in aiding organizations in transitioning from outdated systems to modernized tech stacks.Discover effective strategies for managing significant organizational changes, especially for those new to platforms like Salesforce.Gain insights into building a successful consultancy through Russ's leadership, culture, and client management lessons.In this insightful episode, I sit down with Russ Budgett, a seasoned Salesforce expert and founder of radianhub.com. With over two decades in the software industry, Russ brings much knowledge and experience, particularly from his 14 years in the Salesforce ecosystem. During our conversation, Russ shares his journey of running his own Salesforce practice, focusing on leveraging customer trust and a value-driven approach to fuel business growth. He also discusses the strategic levers tech consultants should pull to enhance their business operations.About Russell Badgett Focused on technology solutions and vertical strategies, Russ has over 20 years of experience in the software industry and 14 years in the Salesforce ecosystem with SaaS-based platforms. A customer-trusted, value-driven approach has been the key to success with enterprise clients such as Sony, Salesforce, P&G, Lilly, Harley-Davidson, and Roche Diagnostics. The mission behind radianHub is to bring this experience and best practices back to the mid-market and public sector (supporting clients of all sizes).Resources and LinksRadianhub.comRuss's LinkedIn profileEmail Russ at russ.badgett@radianhub.comBook a call with RussBook: Buy Back Your TimePrevious episode: 530 - ROI is Killing Your DealCheck out more episodes of The Paul Higgins ShowStrategic Profit Blueprint Join our newsletterJoin the Tech CollectiveSuggested resourcesFind out more about Paul and how he can help you

Janice Y. Chyou, MD, FHRS, Icahn School of Medicine at Mount Sinai, is joined by guest Christine M. Albert, MD, MPH, FHRS, Cedars-Sinai Medical Center and Marina Cerrone, MD, NYU School of Medicine to discuss how Electrocardiogram (ECG) abnormalities have been evaluated as static risk markers for sudden cardiac death (SCD), but the potential importance of dynamic ECG remodeling has not been investigated. In this study, the nature and prevalence of dynamic ECG remodeling were studied among individuals who eventually suffered SCD. https://www.hrsonline.org/education/TheLead https://pubmed.ncbi.nlm.nih.gov/37956651/ Host Disclosure(s): J. Chyou: Honoraria/Speaking/Consulting: McGraw-Hill, American Heart Association, Membership, Advisory Committee: American Heart Association Contributor Disclosure(s): C. Albert: Research: Abbott, Roche Diagnostics, St. Jude Medical, NIH, Honoraria/Speaking/Consulting: Boston Scientific, Medtronic, Element Services, Inc., Illumina, Novartis M. Cerrone: Research: American Heart Association, Honoraria/Speaking/Consulting: StrideBio, Medtronic Inc., BioMarin, Inc., Abbott Medical This episode has .25 ACE credits associated with it. If you want credit for listening to this episode, please visit the episode page on HRS365 https://www.heartrhythm365.org/URL/TheLeadEpisode55

Suja Subramaniam is the VP of Intellectual Property at Roche Diagnostics - a global leader in healthcare diagnostics, providing innovative solutions and cutting-edge technologies for the accurate and efficient detection of diseases. She is a Member of the Diversity and Inclusion Council at Roche Diagnostics. Suja is an Alum of St. Stephens College, University of Notre Dame, and Franklin Pierce Law Center. --- Support this podcast: https://podcasters.spotify.com/pod/show/theindustryshow/support

William H. Sauer, MD, FHRS, CCDS, of Brigham and Women's Hospital is joined by guests Akshay Suvas Desai, MD, MPH of Brigham and Women's Hospital, and Sunil Kapur, MD of Brigham and Women`s Hospital to discuss how the Resynchronization–Defibrillation for Ambulatory Heart Failure Trial (RAFT) showed a greater benefit with respect to mortality at 5 years among patients who received cardiac-resynchronization therapy (CRT) than among those who received implantable cardioverter–defibrillators (ICDs). However, the effect of CRT on long-term survival is not known. We randomly assigned patients with New York Heart Association (NYHA) class II or III heart failure, a left ventricular ejection fraction of 30% or less, and an intrinsic QRS duration of 120 msec or more (or a paced QRS duration of 200 msec or more) to receive either an ICD alone or a CRT defibrillator (CRT-D). We assessed long-term outcomes among patients at the eight highest-enrolling participating sites. The primary outcome was death from any cause; the secondary outcome was a composite of death from any cause, heart transplantation, or implantation of a ventricular assist device.  https://www.hrsonline.org/education/TheLead https://www.nejm.org/doi/full/10.1056/NEJMoa2304542 Host Disclosure(s): W. Sauer: Honoraria/Speaking/Consulting: Biotronik, Biosense Webster, Inc., Abbott, Boston Scientific; Research: Medtronic Contributor Disclosure(s): A. Suvas Desai: Honoraria/Speaking/Consulting: Abbott, Novartis, AstraZeneca, BioFourmis, Regeneron, Alnylam Pharmaceuticals, Bayer Healthcare Pharmaceuticals, Cytokinetics, AxonTherapies, Avidity Biosciences, Medpace, Merck, New Amsterdam Pharma, Parexel, Roche Diagnostics, GlaxoSmithKline, NovoNordisk, Veristat, Verily/Google, Zydus, River2Renal, Research: Bayer Healthcare Pharmaceuticals, Abbott Medical, AstraZeneca, Novartis  S. Kapur: Honoraria/Speaking/Consulting: Medtronic, Novartis, Abbott, Biotronik This episode has .25 ACE credits associated with it. If you want credit for listening to this episode, please visit the episode page on HRS365 https://www.heartrhythm365.org/URL/TheLeadEpisode53

ESC TV Today brings you concise analysis from the world's leading experts, so you can stay on top of what's happening in your field quickly. This episode covers: Cardiology This Week: A concise summary of recent studies Fluid restriction, bed rest, leg compression in acute heart failure Device-detected atrial fibrillation Snapshots  Host: Rick Grobbee Guests: Stephan Achenbach, Carlos Aguiar, Biykem Bozkurt and Paulus Kirchhof Want to watch that episode? Go to: https://esc365.escardio.org/event/1142 Disclaimer This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests Stephan Achenbach, Rick Grobbee and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, Lilly, Novartis, Pfizer, Sanofi, Servier, Tecnimede. Biykem Bozkurt has declared to have potential conflicts of interest to report: consulting for Abbott, Abiomed, American Regent, Amgen, Astra Zeneca, Bayer, Boehringer Ingelheim, Cardurion, Cytokinetics, Daiichi Sankyo, Johnson & Johnson, Lantheus, Liva Nova, Merck, Regeneron, Renovacor, Respicardia/Zoll, Roche, Sanofi-Aventis, Vifor. Davide Capodanno has declared to have potential conflicts of interest to report: Sanofi, Novo Nordisk, Terumo, Medtronic. Paulus Kirchhof has declared to have potential conflicts of interest to report: fees from AstraZeneca, Roche Diagnostics, Johnson&Johnson, Philips, Medtronic, Boehringer-Ingelheim, Daiichi Sankyo. Research fundings from Sanofi Adventis, Abbott, German Ministry of Education and Research (BMBF), Daiichi Sankyo, British Heart Foundation, Leducq Foundation, European Union horizon2020, UK Medical Research Council and NIHR (UK National Institute of Health Research). Emma Svennberg has declared to have potential conflicts of interest to report: institutional research grants from Bayer, Bristol-Myers, Squibb-Pfizer, Boehringer-Ingelheim, Johnson & Johnson, Merck Sharp & Dohme.

ESC TV Today brings you concise analysis from the world's leading experts, so you can stay on top of what's happening in your field quickly. This episode covers: Cardiology This Week: A concise summary of recent studies Current indications for Cardiac Resynchronisation Therapy The polypill for cardiovascular disease prevention Snapshots Host: Perry Elliott Guests: Carlos Aguiar, Cecilia Linde, Valentin Fuster, Stephan Achenbach Want to watch that episode? Go to: https://esc365.escardio.org/event/1139 Disclaimer This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests Stephan Achenbach, Valentin Fuster and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, Lilly, Novartis, Pfizer, Sanofi, Servier, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Sanofi, Novo Nordisk, Terumo, Medtronic. Perry Elliott has declared to have potential conflicts of interest to report: consultancies for Pfizer, BMS, Cytokinetics. Cecilia Linde has declared to have potential conflicts of interest to report: research grants to institutions; Swedish Heart Lung Foundation, Swedish Academy of Science, Stockholm County Council, Roche Diagnostics. Speaker honoria: AstraZeneca, Medtronic, Impulse Dynamics, Vifor, Novartis, Boehringer Ingelheim, MSD, Bayer Advisory Board, AstraZeneca (continuity study), Medtronic (Women and CRT), Medtronic Implementation of CRT and ICD. DSMB: UCS Uppsala ABC Study. Emma Svennberg has declared to have potential conflicts of interest to report: institutional research grants from Bayer, Bristol-Myers, Squibb-Pfizer, Boehringer-Ingelheim, Johnson & Johnson, Merck Sharp & Dohme.

He's been the CEO of Indianapolis-based Roche Diagnostics North America for less than a year, but Brad Moore is already putting his stamp on the healthcare giant. In episode 140, the son of an Ohio banker talks innovation, Indiana, and the importance of being an inclusive leader.

William H. Sauer, MD, FHRS, CCDS, of Brigham and Women's Hospital is joined by Kolade Muchaili Agboola, MD, and Akshay Suvas Desai, MD, MPH, of Brigham and Women's Hospital to discuss the results and implications of the CASTLE-HTx trial.   https://www.hrsonline.org/education/TheLead   Host Disclosure(s): W. Sauer: Honoraria/Speaking/Consulting Fee: Biotronik, Biosense Webster, Inc., Abbott, Boston Scientific; Research (Contracted Grants for PIs Named Investigators Only): Medtronic   Contributor Disclosure(s): K. Agboola: No relevant financial relationships with ineligible companies to disclose.  A. Desai: Honoraria/Speaking/Consulting Fee: Abbott, Novartis, AstraZeneca, BioFourmis, Regeneron, Alnylam Pharmaceuticals, Bayer Healthcare Pharmaceuticals, Cytokinetics, AxonTherapies, Avidity Biosciences, Medpace, Merck, New Amsterdam Pharma, Parexel, Roche Diagnostics, GlaxoSmithKline, NovoNordisk, Veristat, Verily/Google, Zydus, River2Renal; Research (Contracted Grants for PIs Named Investigators Only): Bayer Healthcare Pharmaceuticals, Abbott Medical, AstraZeneca, Novartis

There are various phases of improving Service Management. However, the path might not be entirely clear. But worry not because in this Ticket Volume live episode, Doug Tedder shares an ITSM implementation roadmap! He and Matt discuss where to start, how to mature, and what "good" looks like. Get ready to dive into IT value maximization! Doug Tedder is an IT Consultant and author specialized in helping businesses improve and leverage their use of IT organizations. He currently assists organizations in ITSM plan development, process implementation plans, ITSM and strategy roadmaps, and more. His experience also includes some remarkable roles as the President of itSMF USA, the Director of Managemetn Systems at The priSM Institute, and the Manager of Service Delivery at Roche Diagnostics.

Bryce Ackerman from Roche Diagnostics joins Dave to discuss the role of WFM in CX, some of the biggest myths about WFM and how important honesty and transparency are when dealing with the workforce.  Bryce shares some history of his journey in WFM and some of the life lessons he has learned along the way.

FDA warns of bacterial infection risk and inaccurate results in a recall of SD Biosensor's Pilot COVID-19 At-Home Tests distributed by Roche Diagnostics, affecting numerous lot numbers. The FDA reported that about 500,000 tests were distributed to CVS Health. https://bit.ly/3nBVw7M #WNDNewsCenter #CVSHealth #Amazon #COVID19AtHomeTests #COVID19TestRecalled #FoodAndDrugAdministration #FDA #BacterialInfection #RocheDiagnostics #SpeciesOfBacteria #TheWesternJournal #ClarkCountyToday

Follow me to see #HeadsTalk Podcast Audiograms every Monday on LinkedIn. Episode Title:-

ESC TV Today brings you concise analysis from the world's leading experts, so you can stay on top of what's happening in your field quickly. This episode covers: Cardiology This Week: A concise summary of recent studies HIV and heart disease Congestion and decongestion in acute heart failure: State of the art Mythbusters – Precordial thump in cardiac arrest Host: Rick Grobbee Guests: Priscilla Hsue, Alexandre Mebaaza and Emma Svennberg Want to watch that episode? Go to: https://esc365.escardio.org/event/1028 Disclaimer This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests  Stephan Achenbach, Rick Grobbee and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, Alnylam, Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, Lilly, Novartis, Pfizer, Sanofi, Servier, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Sanofi, Daiichi Sankyo, Terumo, Medtronic, Chiesi. Priscilla Hsue has declared to have potential conflicts of interest to report with Gilead and Merck. Alexandre Mebazaa has declared to have potential conflicts of interest to report: grants from Roche Diagnostics, Abbott, 4TEEN4 and Windtree.  Emma Svennberg has declared to have potential conflicts of interest to report: institutional research grants from Bayer, Bristol-Myers, Squibb-Pfizer, Boehringer- Ingelheim, Johnson & Johnson, Merck Sharp & Dohme.

James Gallagher asks whether a weight-loss drug on the NHS heralds a new era in tackling obesity? He meets Jan who lost nearly 4 stone after being part of a trial taking a weekly injection of Semaglutide for 15 months alongside advice on meals and exercise. However, when people stop taking the drug the weight starts to go back on. Add to that supply shortages with heightened private demand and some doctors think the drug is as controversial as they come. James unpicks the ethical and societal dilemmas against a backdrop of half the world's population projected to be overweight or obese by 2035. Producer: Erika Wright Declared interests Dr Margaret McCartney: "No conflicts to declare." Prof Sir Stephen O'Rahilly : "in the past has been a remunerated consultant and has had research collaboration with Novo Nordisk." Professor Naveed Sattar: "consulted for and/or received speaker honoraria from Novo Nordisk, Abbott Laboratories, Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Hanmi Pharmaceuticals, Merck Sharp & Dohme, Novartis, Pfizer, and Sanofi; and grant support paid to his university from AstraZeneca, Boehringer Ingelheim, Novartis, and Roche Diagnostics. He was a co-investigator in lifestyle trials such as DiRECT and co-lead for STANDby."

On episode 411 of The Nurse Keith Show nursing and healthcare career podcast, Keith interviews French biomedical engineer and podcaster Mathieu Chaffard, regarding Mathieu's podcast — Impulse: Meeting Healthcare Pioneers — and his perspective on the European zeitgeist when it comes to healthcare innovation and emerging technologies in the 21st century. Mathieu is a French biomedical engineer, trained at the Swiss Federal Institute of Technology in Lausanne. Passionate about medical technology applied to cardiac indications, he has occupied different technical roles in Europe, including Development Engineer for B. Braun in Berlin and Field Specialist for Abbott in Paris, before moving to project management in the digital health space for Roche Diagnostics in Zürich. Wishing to share his passion for medical progress on a broad scale and driven by an ongoing desire to learn more about its aspects, he has decided to create his own show where he talks with entrepreneurs, researchers and physicians about their personal journey and the innovative technologies they are developing to transform patients' lives. Connect with Mathieu: Impulse: Meeting Healthcare Pioneers podcast LinkedIn Instagram Twitter YouTube ----------- Did you know that you can now earn CEUs from listening to podcasts? That's right — over at RNegade.pro, they're building a library of nursing podcasts offering continuing education credits, including episodes of The Nurse Keith Show! So just head over to RNegade.pro, log into the portal, select Nurse Keith (or any other Content Creator) from the Content Creator dropdown, and get CEs for any content on the platform! Nurse Keith is a holistic career coach for nurses, professional podcaster, published author, award-winning blogger, inspiring keynote speaker, and successful nurse entrepreneur. Connect with Nurse Keith at NurseKeith.com, and on Twitter, Facebook, LinkedIn, and Instagram. Nurse Keith lives in beautiful Santa Fe, New Mexico with his lovely fiancée, Shada McKenzie, a highly gifted traditional astrologer and reader of the tarot. You can find Shada at The Circle and the Dot. The Nurse Keith Show is a proud member of The Health Podcast Network, one of the largest and fastest-growing collections of authoritative, high-quality podcasts taking on the tough topics in health and care with empathy, expertise, and a commitment to excellence. The podcast is adroitly produced by Rob Johnston of 520R Podcasting, and Mark Capispisan is our stalwart social media manager and newsletter wrangler.

Brad provides leadership in strategic planning, marketing, mergers and acquisitions, business partnerships, and joint ventures for Jabil's $3 billion healthcare division. With over 12 years of experience in senior business development and finance roles, Brad has exceptional insight and understanding of the technology, policy, and macroeconomic forces shaping today's dynamic healthcare marketplace. Before joining the healthcare division's executive team in 2012, Brad held positions with Flextronics Medical (formerly Avail Medical Products), Roche Diagnostics, and Fresenius.Jabil is a global manufacturing service and Fortune 200 company with over 250,000 employees across 100 locations in 30 countries. At Jabil, they make the most complex ideas and products a reality. They combine unmatched breadth and depth of end-market experience, technical and design capabilities, manufacturing know-how, supply chain insights, and global product management expertise to enable success for the world's leading brands.

Show Description: Bridget Boyle is the Head of People & Culture for Roche Diagnostics' U.S. Diagnostics Commercial Organization, as part of the HR Shared Service Center that supports all Roche employees in North America. She also contributes as a member of Roche's Global Diagnostics HR Leadership Team. In this interview, Bridget not only highlights key moments in her career path, but she also provides actionable lessons on networking at a company, how to make yourself more valuable for an organization, and what leaders can do to maximize the talent around them. Show Highlights: 3:45-11:15: We begin the show recapping our experiences with the cold plunge tub, Bridget's motivation for starting cold plunge last year, and long-term health benefits. 11:15-22:15: Bridget dives into her professional background, how she found her love for the outdoors, and a memorable job she had early in her career that influenced her passion for building relationships. She also provides advice to individuals who are considering a gap year before or after college. 22:15-36:45: Bridget explains how to network effectively at an organization, what to do when you are stuck in a role, how to be proactive in asking for what you want, and leveraging your "superpowers" to unlock meaningful career opportunities. 36:45-43:45: Bridget reflects on a major career inflection point and hurdles she had to overcome when moving across the country for an HR leadership job. 43:45-58:15: Bridget highlights the big projects she's taken on in her HR leadership roles at Roche, how her and her internal partners are using data analytics to develop talent, and how to spark motivation and innovation across the enterprise. 58:15-1:15:45: Bridget outlines what her company did from an HR perspective to support employees during the pandemic, transitioning from 100% remote work to hybrid work, and how her organization keeps employees engaged. 1:15:45-1:36:45: We end the show by asking Bridget about any passion projects, what she is looking to achieve this coming year, and how she wants to be remembered.

Steve Lodin, a veteran of the cybersecurity industry, embarks on an ambitious mission to protect millions of identities from hackers while his team strives to maintain high-security standards and compliance with regulators."The more that we can identify, document, and share, the less attacks that are hitting our colleagues and our peers in the industry." - Steve LodinLodin's experience comes with a background in software engineering, system administration, and global IT security. He has worked with General Motors, Ernst and Young, Roche Diagnostics, and Sallie Mae, and has a Master's degree in Computer Science from Purdue University.Steve Lodin had been working with electronics engineering and software engineering since he got his engineering degree. He had a passion for computers and decided to focus on security. He went back to school for a Master's in Computer Science and went on to work at Ernst and Young, Roche Diagnostics, and the world of startups. For the past 10 years, he has been working at Sallie Mae protecting millions of IDs from hackers. With the shift to the cloud, Steve has been advocating for the removal of legacy security debt and providing security opportunities to improve the environment. He is a prominent contributor to the industry, helping to identify and document attacks to protect against them.In this episode, you will learn the following:1. What challenges arise when attempting to secure xIoT devices?2. How can organizations prevent external and internal attack surfaces?3. How can organizations use the cloud to reduce their legacy security debt? Let's get into Things on the IoT Security Podcast!Follow Brian Contos on LinkedIn at https://www.linkedin.com/in/briancontosAnd you can follow John Vecchi at https://www.linkedin.com/in/johnvecchiThe IoT Security Podcast is powered by Phosphorus Cybersecurity. Join the conversation for the IoT Security Podcast — where xIoT meets Security. Learn more at https://phosphorus.io/podcast

Tips About Building A Start Up 2023 - How To Succeed With A Startup | Dr. Kim & Todd Saxton https://campsite.bio/narontillman1Did you know that 70% of startups fail? That means that only 30% of businesses started goes on to see some measure of success. Today's guest Dr. Kim & Todd Saxton assist entrepreneurs through the hurdles they may face as start-up owners. Listen as we explore in a in depth conversation concerning this matter. WHO IS DR KIM & TODD SAXTON?Kim and Todd have advised, helped launch, and invested in hundreds of startups spanning life sciences, software, sports, consumer products, andservices. They serve on various boards of entrepreneurial ventures and startup advisory associations. The pair have shared their expertise from the stage to dozens of audiences, including entrepreneurship and professional developmentassociations, academic societies, and global companies like Roche Diagnostics and Pfizer Pharmaceuticals.Contact Our Guest:https://www.amazon.com/Titanic-Effect-Successfully-Navigating-Uncertainties/dp/1642792144

Ben is joined by two giants of global health diplomacy, Ambassadors Mark Dybul and Eric Goosby, to take stock of how resilient the world is in sustaining existing infectious disease responses and preparing for future pandemic threats, by building on existing infrastructure - particularly optimized lab-based diagnostic networks. A Shot In the Arm Podcast is a member of the Health Podcast Network, and is a project of the Global Health Reporting Center. This episode is brought to you with the kind support of Roche Diagnostics.  Guests Ambassador Mark Dybul, Co-Director of the Center for Global Health Practice and Impact and Professor in the Department of Medicine at Georgetown University Ambassador Eric Goosby, Professor of Medicine and Director of Global Health Delivery and Diplomacy, Institute for Global Health Sciences, UCSF. https://cghpi.georgetown.edu https://globalhealthsciences.ucsf.edu https://theindependentpanel.org https://www.state.gov/pepfar https://www.theglobalfund.org/en https://cop27.eg #pandemics #HIV #AIDS #TB #Malaria #COVID #climatecrisis #onehealth #COP27 #WHO #UNAIDS #GlobalFund #PEPFAR #Diagnostics #Vaccines #Treatments #Laboratories #PointOfCare #Monitoring #Infectiousdisease #globalhealthdiplomacy #resilience

Follow me to see #HeadsTalk Podcast Audiograms every Monday on LinkedIn. Episode Title:-

Ben catches up with infectious disease physicians Tamar Tchelidze and Ben La Brot, on how networks of lab-based and point of care tests can drive better diagnosing and management of infectious disease - and can PrEP and HIV treatment be the poster-child to prove this to skeptical policy makers? Sponsored by Roche Diagnostics. Guests Dr. Tamar Tchelidze, Disease Partner, Medical & Scientific Affairs, Roche Diagnostics Dr. Benjamin LaBrot, Medical Affairs Leader, Infectious Disease, Medical & Scientific Affairs, Roche Diagnostics https://www.who.int https://www.unaids.org/en https://www.cdc.gov https://diagnostics.roche.com https://www.ashotinthearmpodcast.com #infectiousdisease #pandemics #covid #HIV #AIDS #tb #malaria #pandemicsresponse #diagnostics #laboratory #treatment #testing #prevention #screening #PrEP #injectables

In this episode of The Venture, we share a conversation with Moritz Hartmann, global head of Roche Information Solutions for Roche Diagnostics, one of the Swiss multinational's two divisions. Adapting to constant technological change and disrupting via science has fueled the 125-year-old company's longevity, which now uses digital tools and data science to provide insights, drive outcomes, and deliver personalized healthcare. Hartmann sat down with McKinsey's Anand Swaminathan to explain his mission to innovate the company's diagnostic solutions through the adoption of new technology, giving product teams the freedom to operate without interference from above, and never forgetting to let patient needs guide the business.See www.mckinsey.com/privacy-policy for privacy information

ESC TV Today brings you concise analysis from the world's leading experts, so you can stay on top of what's happening in your field quickly. This episode tackles: Cardiology this Week Factor XIa Inhibitors: A Breakthrough in Anticoagulation? Heart Failure Treatment: New Concepts for 2023 and Beyond Snapshots Host: Susanna Price Guests: Carlos Aguiar, Robert Storey, Carolyn Lam and Stephan Achenbach Want to watch that episode? Go to: https://esc365.escardio.org/event/602 Disclaimer: This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests Stephan Achenbach, Nicolle Kraenkel, Susanna Price and Robert Storey declared to have no potential conflict of interest to report. Carlos Aguiar declared to have potential conflict of interest to report: personal fees for consultancy and/or speaker fees from Abbott, Alnylam, Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, Lilly, Novartis, Pfizer, Sanofi, Servier, Tecnimede. Davide Capodanno declared to have potential conflict of interest to report: Sanofi, Daiichi Sankyo, Terumo, Medtronic, Chiesi. Carolyn Lam declared to have potential conflict of interest to report: Carolyn S.P. Lam is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; has received research support from Bayer and Roche Diagnostics; has served as consultant or on the Advisory Board/ Steering Committee/ Executive Committee for Actelion, Alleviant Medical, Allysta Pharma, Amgen, AnaCardio AB, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Cytokinetics, Darma Inc., EchoNous Inc, Eli Lilly, Impulse Dynamics, Intellia Therapeutics, Ionis Pharmaceutical, Janssen Research & Development LLC, Medscape/WebMD Global LLC, Merck, Novartis, Novo Nordisk, Prosciento Inc, Radcliffe Group Ltd., ReCor Medical, Roche Diagnostics, Sanofi, Siemens Healthcare Diagnostics and Us2.ai; and serves as co-founder & non-executive director of Us2.ai. Emma Svennberg declared to have potential conflict of interest to report: Institutional research grants from Bayer, Bristol-Myers, Squibb-Pfizer, Boehringer- Ingelheim, Johnson & Johnson, Merck Sharp & Dohme

You've probably spent your entire life believing that you should do what you're good at. Surely, if you're a natural at something, then it's your life's calling, right? But what if you've been wrong all along? Gary Hobbs, electrical engineer turned entrepreneur, believes it's the challenges you face, doing what you love, and doing what you're GREAT at will drive your success. In this episode of the Hot Mess Hotline, you will hear how important it is to weigh the risks of doing what you're good at when you're feeling unfulfilled. Can you find freedom by facing challenges and being fulfilled by chasing your passion? Gary took a leap that changed the course of his career. Although initially he felt like he made a big Hot Mess, what he really uncovered was his passion, his calling, and more success than he could have ever dreamed of. Exploring the tension of leaving a successful business for the unknown was a leap of faith, but it's usually the biggest leaps that have largest rewards. Join Gary and myself as we talk all things risk, reward, failure, success, and overcoming challenges on this interview. You will laugh along side us, learn several lessons listed below, but most of all, you will be challenged to ask yourself if you're comfortable enough to step out from behind the ease of success to embrace the risk of facing challenges to uncover your greatest passions. Here are a few lessons that Gary learned the hard way so we don't have to : More focus equals more success Not all skills are transferable Just because you're good at something doesn't mean you should stick with it Success is more than just money If you can let go of what isn't your work to do, you'll see greater blessings Increased confidence comes from overcoming challenges Humility comes from understanding there are some external factors that could shut down your business or career Use your faith and spirituality to stay grounded Empathy is the ultimate leadership skill About Gary Hobbs Gary Hobbs is an entrepreneur and former corporate executive with extensive experience in real estate, technology, education, and healthcare. He started his career as an electrical design engineer and has successfully migrated through the corporate ranks of companies like AT&T, Eli Lilly, and Roche Diagnostics. As an engineer, project manager, business executive, developer, and entrepreneur he has led organizations of up to four hundred people and budget responsibilities spanning well over $100M. Currently, he is CEO for Black and White Investments, LLC. Gary founded BWI in 2005 as a development and construction management company. BWI's target market is urban development within Indiana and their primary focus is multi-family and mixed-use tax credit developments. About BWI BWI, LLC is a construction, real estate development, property management, consulting and electrical firm in the greater Indianapolis area that focuses on not only construction management of general, large development projects, but also niche, energy-efficient urban revitalization projects. BWI has extensive capabilities helping clients design, develop and manage their projects with a special emphasis in electrical and eco-friendly, sustainable development. Their development and construction services can be accomplished under a consultative or design-build basis. BWI, founded in 2005, is headquartered in Indianapolis, Indiana. Their number one aspiration is to bring hope to under-served urban communities via economic development that align with their Quality of Life aspirations and initiating in collaborative partnerships. Lead Kick Ass Meetings: Complimentary Resource Meetings are a really expensive use of your time. It only makes sense that they need to be more productive and valuable. Instead of running meetings that could have been an email, lead powerful meetings that have purpose, participation, and problem solving.  

https://www.patreon.com/datameshradio (Data Mesh Radio Patreon) - get access to interviews well before they are released Episode list and links to all available episode transcripts (most interviews from #32 on) https://docs.google.com/spreadsheets/d/1ZmCIinVgIm0xjIVFpL9jMtCiOlBQ7LbvLmtmb0FKcQc/edit?usp=sharing (here) Provided as a free resource by DataStax https://www.datastax.com/products/datastax-astra?utm_source=DataMeshRadio (AstraDB) Transcript for this episode (https://docs.google.com/document/d/1JyEGeFHqLz3_WdGviNZeAYMJZQzI8ttS9r8I5ffqqwo/edit?usp=sharing (link)) provided by Starburst. See their Data Mesh Summit recordings https://www.starburst.io/learn/events-webinars/datanova-on-demand/?datameshradio (here) and their great data mesh resource center https://www.starburst.io/info/distributed-data-mesh-resource-center/?datameshradio (here) In this episode, Scott interviewed Omar Khawaja, Head of Business Intelligence at Roche Diagnostics. To be clear, Omar was only representing his own viewpoints and learnings, not necessarily those of Roche. Some interesting thoughts/takeaways from Omar's point of view and learnings: If you are going to make progress in a data mesh journey, you must be okay with "good enough". Perfect is the enemy of good and done. Measure, learn, and adjust along the way but get moving and keep moving. It's okay to make mistakes - recognize and correct them. Echoing a number of past guests, change management and organizational challenges will take a large portion of a data mesh implementation leader's time and effort - likely far more than most would expect. Focus on empowering people and showing them why this can work for them. And what it means for them. Data mesh cannot be your entire data strategy. If you are implementing data mesh, it must only be part of your data strategy. Start from the why. Why undertake something as transformational and difficult as implementing data mesh? What business value will it deliver? Data-as-a-product thinking is the true heart of a data mesh implementation. It's far more than just creating data products. Data product discovery is crucial, much like discovery in regular product management. Take considerable learnings from product management in other disciplines. Focus on outcomes in day-to-day data work. What are you trying to deliver? What is the value in it? For whom? How will we measure if we are successful? And were we actually successful? We need to get data people to rethink creating point solutions - sometimes called project management thinking - where they deliver a dashboard and the dashboard itself is the focus. This leads to fragility that could be prevented by focusing on the entire data lifecycle to create the dashboard with the dashboard - and many other chances for data reuse - as an output. Roche is being quite flexible around who develops data products - it is all about the capabilities and needs. Often, it is data engineers in the domains, enabled by the central platform team. But it can be data/business analysts or software engineers too. If the data product isn't overly complex or if a business analyst really understands data, why can't they be the data product developer? It would have been the definition of insanity - trying the same thing over and over and expecting different results - for Roche to just move from an on-prem data lake that was having scaling and quality issues to a cloud data lake. Many other aspects needed to change. The organization needed to unlearn and relearn a number of things and data mesh was a great vision for where they could go. Roche saw some duplication of work across data products so they adjusted and made their data product discovery and design phases very public. Making it public can increase collaboration early in a data product's life as well so you might find additional data consumers in the development phase. Omar started the conversation with a definition of what Business...

In this episode, Amanda is joined by her friend an co-collaborator Erika Brooke. They discuss the topic of psychological safety and building spaces that feel safe to ask questions without being humiliated or retaliated against. This is an extremely important topic considering today's world climate, so this is a conversation you definitely don't want to miss! Guest Information: Erica has been in the Pharmaceutical and Diagnostics industry for nearly 22 years, with the past 7 being at Roche Diagnostics building a team and strategy for biospecimen acquisition for clinical trials. In her role, Biospecimen Acquisition and Strategy Lead, she and her team coordinated efforts to procure specimens for Covid test development, among many other disease areas. Erica is also a writer, poet, cook and death doula who shares her art under the name Erika Brooke. Website: www.erikabrooke11.com Instagram: @erikabrooke11 @erikabrookehaven Did you enjoy this episode? Let me know your thoughts! Instagram - @amanda_flaker https://www.instagram.com/amanda_flaker/ If you're interested in more of my work, be sure to visit my YouTube channel: Search "Amanda Flaker" or CLICK HERE